EU watchdog assessing Dexamethasone Taw as possible COVID-19 drug

The European health regulator said on Wednesday it was evaluating Taw Pharma’s branded steroidal drug dexamethasone as a potential COVID-19 treatment for hospitalised adult patients after it received an application from the drug developer. The European Medicines Agency (EMA) said in a statement its human medicines committee (CHMP) would weigh-in on the application for Dexamethasone Taw within the shortest timeline possible. Europe is already evaluating the decades old dexamethasone for COVID-19 after it garnered international attention when a study, dubbed RECOVERY, showed in June the drug reduced death rates by about a third in severely ill, hospitalised COVID-19 patients. The EMA said results from RECOVERY would be considered in the assessment of Dexamethasone Taw.